The program gathers real-world data from patient registries and through health insurers as well as care facilities to monitor long-term safety of prescription medications.
Prescription drugs, especially for people with chronic conditions like diabetes or blood pressure, can help manage or improve a patient's condition. Studies have shown that a majority of Medicare beneficiaries take at least 1 medicine for a chronic condition, and 25% take 5 or more. However, while clinical trials evaluate the safety of these medications, trials are conducted for only finite time period. Patients who take these drugs for chronic conditions do so for extended periods of time,even lifelong. Additionally, trials are conducted in a controlled environment; real-world patients would provide the actual data on long-term effects, drug-drug interactions, drug-food interactiosn, etc. An apt example of this would be the pain medication Vioxx. Approved in 1999, studies and analyses done after Vioxx hit the market confirmed that it raised the risk of heart attack and nearly 40,000 people died as a direct or indirect result of taking the drug before it was taken off the market in 2004.
In May 2008, HHS and the FDA launched the Sentinel Initiative to improve post-marketing surveillance of prescription drugs and to avoid tragedies like Vioxx. The Sentinel network consists primarily of 18 organizations, including large health insurers (Aetna, Anthem, Humana, and Kaiser Permanente), various disease registries, hospitals, and in-patient facilities.
Read more about the program on Health Affairs: http://bit.ly/1FWzzjg
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More